Literature DB >> 21584646

Systemic therapy options for unresectable and metastatic chordomas.

Silvia Stacchiotti1, Paolo Giovanni Casali.   

Abstract

Chordoma is an exceedingly rare tumor, marked by a slow growth rate. Surgery is the treatment of choice, but the most frequent sites of origin (spine and skull base) make treatment of primary disease challenging. Local relapses affect more than 50% of cases, with a minority of patients being cured by further surgery. Furthermore, metastases occur in at least 20% of patients. For residual or recurrent disease, high-dose radiation therapy may be indicated. Radiation therapy is currently the preferred local treatment when surgery is problematic, exploiting most recent techniques, including proton beams and carbon ions. However, systemic therapy is needed in patients non-amenable to surgery and/or radiation therapy. We reviewed systemic treatments currently available, and targets possibly druggable in the future in this orphan disease.

Entities:  

Mesh:

Year:  2011        PMID: 21584646     DOI: 10.1007/s11912-011-0176-x

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN: 1523-3790            Impact factor:   5.075


  83 in total

1.  A multidisciplinary team approach to skull base chordomas.

Authors:  H A Crockard; T Steel; N Plowman; A Singh; J Crossman; T Revesz; J L Holton; A Cheeseman
Journal:  J Neurosurg       Date:  2001-08       Impact factor: 5.115

2.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

Authors:  P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther
Journal:  J Natl Cancer Inst       Date:  2000-02-02       Impact factor: 13.506

Review 3.  Ras, PI(3)K and mTOR signalling controls tumour cell growth.

Authors:  Reuben J Shaw; Lewis C Cantley
Journal:  Nature       Date:  2006-05-25       Impact factor: 49.962

4.  Molecular and biochemical analyses of platelet-derived growth factor receptor (PDGFR) B, PDGFRA, and KIT receptors in chordomas.

Authors:  Elena Tamborini; Francesca Miselli; Tiziana Negri; M Stefania Lagonigro; Samantha Staurengo; Gian Paolo Dagrada; Silvia Stacchiotti; Elisa Pastore; Alessandro Gronchi; Federica Perrone; Antonino Carbone; Marco A Pierotti; Paolo G Casali; Silvana Pilotti
Journal:  Clin Cancer Res       Date:  2006-12-01       Impact factor: 12.531

5.  Patient outcome at long-term follow-up after aggressive microsurgical resection of cranial base chordomas.

Authors:  Fortios Tzortzidis; Foad Elahi; Donald Wright; Sabareesh K Natarajan; Laligam N Sekhar
Journal:  Neurosurgery       Date:  2006-08       Impact factor: 4.654

6.  Long-term results: adjuvant radiotherapy in en bloc resection of sacrococcygeal chordoma is advisable.

Authors:  Wouter A Moojen; Carmen L A Vleggeert-Lankamp; Augustinus D G Krol; Sander P D Dijkstra
Journal:  Spine (Phila Pa 1976)       Date:  2011-05-01       Impact factor: 3.468

7.  Imatinib mesylate induces cisplatin hypersensitivity in Bcr-Abl+ cells by differential modulation of p53 transcriptional and proapoptotic activity.

Authors:  Ioanna Skorta; Moshe Oren; Christiane Markwardt; Matthias Gutekunst; Walter E Aulitzky; Heiko van der Kuip
Journal:  Cancer Res       Date:  2009-12-15       Impact factor: 12.701

8.  Aberrant hyperactivation of akt and Mammalian target of rapamycin complex 1 signaling in sporadic chordomas.

Authors:  Sangyeul Han; Carolyn Polizzano; Gunnlaugur P Nielsen; Francis J Hornicek; Andrew E Rosenberg; Vijaya Ramesh
Journal:  Clin Cancer Res       Date:  2009-03-10       Impact factor: 12.531

9.  Sacrococcygeal chordomas in patients with tuberous sclerosis complex show somatic loss of TSC1 or TSC2.

Authors:  Lisa Lee-Jones; Irene Aligianis; Peter A Davies; Ana Puga; Peter A Farndon; Anat Stemmer-Rachamimov; Vijaya Ramesh; Julian R Sampson
Journal:  Genes Chromosomes Cancer       Date:  2004-09       Impact factor: 5.006

10.  Analysis of receptor tyrosine kinases (RTKs) and downstream pathways in chordomas.

Authors:  Elena Tamborini; Emanuela Virdis; Tiziana Negri; Marta Orsenigo; Silvia Brich; Elena Conca; Alessandro Gronchi; Silvia Stacchiotti; Giacomo Manenti; Paolo G Casali; Marco A Pierotti; Silvana Pilotti
Journal:  Neuro Oncol       Date:  2010-02-17       Impact factor: 12.300

View more
  15 in total

1.  Characteristics and overall survival in pediatric versus adult skull base chordoma: a population-based study.

Authors:  Jordan C Xu; Brandon M Lehrich; Tyler M Yasaka; Brendan M Fong; Frank P K Hsu; Edward C Kuan
Journal:  Childs Nerv Syst       Date:  2021-01-18       Impact factor: 1.475

Review 2.  Chordoma in children: Case-report and review of literature.

Authors:  Jean-Louis Habrand; Jean Datchary; Stéphanie Bolle; Anne Beaudré; Ludovic de Marzi; Kévin Beccaria; Dinu Stefan; Jacques Grill; Rémi Dendale
Journal:  Rep Pract Oncol Radiother       Date:  2015-12-08

Review 3.  Immunotherapy as a Potential Treatment for Chordoma: a Review.

Authors:  Shalin S Patel; Joseph H Schwab
Journal:  Curr Oncol Rep       Date:  2016-09       Impact factor: 5.075

4.  STAT3 Inhibition as a Therapeutic Strategy for Chordoma.

Authors:  Anthony C Wang; John H Owen; Waleed M Abuzeid; Shawn L Hervey-Jumper; Xiaobing He; Mikel Gurrea; Meijuan Lin; David B Altshuler; Richard F Keep; Mark E Prince; Thomas E Carey; Xing Fan; Erin L McKean; Stephen E Sullivan
Journal:  J Neurol Surg B Skull Base       Date:  2016-05-31

5.  Metastatic Chordoma: Report of the Two Cases and Review of the Literature.

Authors:  Saurabh Rohatgi; Nikhil H Ramaiya; Jyothi P Jagannathan; Stephanie A Howard; Atul B Shinagare; Katherine M Krajewski
Journal:  Eurasian J Med       Date:  2015-06

6.  Advancement of PI3 Kinase Inhibitor Combination Therapies for PI3K-Aberrant Chordoma.

Authors:  Molly E Heft Neal; Nicole L Michmerhuizen; Kevin J Kovatch; John Henry J Owen; Jingyi Zhai; Hui Jiang; Erin L McKean; Mark E P Prince; J Chad Brenner
Journal:  J Neurol Surg B Skull Base       Date:  2020-10-12

Review 7.  Reprint of "Chordoma in children: Case-report and review of literature".

Authors:  Jean-Louis Habrand; Jean Datchary; Stéphanie Bolle; Anne Beaudré; Ludovic de Marzi; Kévin Beccaria; Dinu Stefan; Jacques Grill; Rémi Dendale
Journal:  Rep Pract Oncol Radiother       Date:  2016-04-18

8.  Immune Myocarditis Overlapping With Myasthenia Gravis Due to Anti-PD-1 Treatment for a Chordoma Patient: A Case Report and Literature Review.

Authors:  Shujing Liang; Jingxian Yang; Yun Lin; Tong Li; Wenrong Zhao; Jun Zhao; Chunyan Dong
Journal:  Front Immunol       Date:  2021-07-08       Impact factor: 7.561

9.  Erlotinib inhibits growth of a patient-derived chordoma xenograft.

Authors:  I-Mei Siu; Jacob Ruzevick; Qi Zhao; Nick Connis; Yuchen Jiao; Chetan Bettegowda; Xuewei Xia; Peter C Burger; Christine L Hann; Gary L Gallia
Journal:  PLoS One       Date:  2013-11-15       Impact factor: 3.240

10.  A novel chordoma xenograft allows in vivo drug testing and reveals the importance of NF-κB signaling in chordoma biology.

Authors:  Matteo M Trucco; Ola Awad; Breelyn A Wilky; Seth D Goldstein; Ruili Huang; Robert L Walker; Preeti Shah; Varalakshmi Katuri; Naheed Gul; Yuelin J Zhu; Edward F McCarthy; Ido Paz-Priel; Paul S Meltzer; Christopher P Austin; Menghang Xia; David M Loeb
Journal:  PLoS One       Date:  2013-11-06       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.